Allogeneic hematopoietic stem cell transplantation with fludarabine, melphalan, and total body irradiation as a conditioning for elderly patients with myeloid malignancies

DOI Web Site PubMed 20 References
  • NAKAMURA Yukinori
    Division of Hematology, Department of Medicine, Keio University School of Medicine Third Department of Internal Medicine, Yamaguchi University School of Medicine
  • MORI Takehiko
    Division of Hematology, Department of Medicine, Keio University School of Medicine
  • KATO Jun
    Division of Hematology, Department of Medicine, Keio University School of Medicine
  • AISA Yoshinobu
    Division of Hematology, Department of Medicine, Keio University School of Medicine Department of Hematology, Yokohama Municipal Citizen's Hospital
  • NAKAZATO Tomonori
    Division of Hematology, Department of Medicine, Keio University School of Medicine Department of Hematology, Yokohama Municipal Citizen's Hospital
  • SHIGEMATSU Naoyuki
    Department of Radiology, Keio University School of Medicine
  • OKAMOTO Shinichiro
    Division of Hematology, Department of Medicine, Keio University School of Medicine

Bibliographic Information

Other Title
  • 高齢者骨髄性造血器腫瘍に対するフルダラビン/メルファラン/全身放射線照射を前処置とした同種造血幹細胞移植
  • 臨床研究 高齢者骨髄性造血器腫瘍に対するフルダラビン/メルファラン/全身放射線照射を前処置とした同種造血幹細胞移植
  • リンショウ ケンキュウ コウレイシャ コツズイセイ ゾウケツキ シュヨウ ニ タイスル フルダラビン/メルファラン/ゼンシン ホウシャセン ショウシャ オ マエショチ ト シタ ドウシュ ゾウケツ カン サイボウ イショク

Search this article

Description

A variety of reduced-intensity conditionings have been used in the reported studies of allogeneic hematopoietic stem cell transplantation (HSCT) for elderly patients with myeloid hematological malignancies. This study retrospectively analyzed the outcome of allogeneic HSCT for 10 patients aged 50 years or older with myeloid hematological malignancies after conditioning with fludarabine (125mg/m2), melphalan (140mg/m2) and total body irradiation (TBI; 8Gy). Median age of the patients was 56.5 years, and diagnoses included acute myelogenous leukemia, advance myelodysplastic syndrome, and secondary myelofibrosis. Sources of stem cells were bone marrow from sibling (n=4) or unrelated donor (n=6). Both overall and disease-free survival rates were 40.0% (95% CI: 10.6∼69.4%). Causes of death were relapse (n=2), fungal infection (n=2), and secondary malignancies (n=2). Because of a high incidence of transplant-related mortality, further refinement of this conditioning is required.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 53 (3), 318-322, 2012

    The Japanese Society of Hematology

References(20)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top